Preclinical perspectives on platinum resistance

Drugs

Volumn 59, Issue SUPPL. 4, 2000, Pages 1-8

  Kelland, Lloyd R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM; AMPHOTERICIN B; BBR 3464; CISPLATIN; DIGITONIN; GLUTATHIONE; METALLOTHIONEIN; OUABAIN; OXALIPLATIN;

ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; DNA BINDING; DNA DAMAGE; DRUG ANTAGONISM; DRUG INACTIVATION; DRUG MECHANISM; DRUG UPTAKE; HUMAN; OVARY CANCER; REVIEW;

FALLOPIA; STROPHANTHUS GRATUS;

EID: 0034036384     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200059004-00001     Document Type: Review

References (46)

1. Rosenberg B. Fundamental studies with cisplatin. Cancer 1985; 55: 2303-16
2. Judson I, Kelland LR. New developments and approaches in the platinum arena. Drugs 2000; 59 Suppl. 4: 29-36
3. Fichtinger-Schepman AM, van der Veer JL, den Hartog JH, et al. Adducts of the antitumour drug cis-diamminedichloroplatinum(II) with DNA: formation, identification and quantitation. Biochemistry 1985; 24: 707-13
4. Comess KM, Lippard SJ. Molecular aspects of platinum-DNA interactions. In: Neidle S, Waring M, editors. Molecular aspects of anticancer drug-DNA interactions. Vol 1. London: The Macmillan Press Ltd, 1993: 134-68
5. Takahara PM, Rosenzweig AC, Frederick CA, et al. Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature 1995; 377: 649-52
6. Huang H, Zhu L, Reid BR, et al. Solution structure of a cisplatin-induced DNA interstrand cross-link. Science 1995; 270: 1842-5
7. Fraval HN, Rawlings CJ, Roberts JJ. Increased sensitivity of UV-repair-deficient human cells to DNA bound platinum products which unlike thymine dimers are not recognized by an endonuclease extracted from Micrococcus luteus. Mutat Res 1978; 51 (1): 121-32
8. Reed E, Ozols RF, Tarone R, et al. Platinum DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Science USA 1987; 84: 5024-8
9. Eastman A, Barry MA. Interaction of trans-diamminedichloroplatinum(II) with DNA: formation of monofunctional adducts and their reaction with glutathione. Biochemistry 1987; 26: 3303-7
10. Szymkowski DE, Yarema K, Essigmann JM, et al. An intrastrand d(GpG) platinum crosslink in duplex M13 DNA is refractory to repair by human cell extracts. Proc Natl Acad Science USA. 1992; 89: 10772-6
11. Zwelling LA, Anderson T, Kohn KW. DNA-protein and DNA interstrand cross-linking by cis- and trans-platinum(II) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity. Cancer Res 1979; 39 (2 Pt 1): 365-9
12. Knox RJ, Friedlos F, Lydall DA, et al. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine- (1,1-cyclobutanedicarboxylato) platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 1986; 46 (4 Pt 2): 1972-9
13. Kelland LR, Mistry P, Abel G, et al. Mechanism-related circumvention of acquired cis-diamminedichloro platinum (II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum (IV) dicarboxylates. Cancer Res 1992; 52: 3857-64
14. Hills CA, Kelland LR, Abel G, et al. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br J Cancer 1989; 59: 527-34
15. Johnson SW, Ferry KV, Hamilton TC. Recent insights into platinum drug resistance in cancer. Drug Resist Updates 1998; 1: 243-54
16. Gately DP, Howell SB. Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 1993; 67: 1171-5
17. Andrews PA. Cisplatin accumulation. In: Kelland LR, Farrell NP, editors. Platinum-based drugs in cancer therapy. Totowa: Humana Press, 2000: 89-113
18. Kool M, de Haas M, Scheffer GL, et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4 and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 1997; 57 (16): 3537-47
19. Ishikawa T, Ali-Osman F. Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. J Biol Chem 1993; 268: 20116-25
20. Mistry P, Kelland LR, Abel G, et al. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer 1991; 64: 215-20
21. Kelley SL, Basu A, Teicher BA, et al. Overexpression of metallothionein confers resistance to anticancer drugs. Science 1988; 241: 1813-5
22. Chaney SG, Sancar A. DNA repair: enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst 1996; 88: 1346-60
23. Kelland LR, Mistry P, Abel G, et al. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular non-seminomatous germ cell line. Cancer Res 1992; 52: 1710-6
24. Zhen W, Link CJ, O'Connor PM, et al. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol 1992; 12: 3689-98
25. Dabholkar M, Bostick-Bruton F, Weber C, et al. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 1992; 84: 1512-7
26. Vilpo JA, Vilpo LM, Szymkowski DE, et al. An XPG DNA repair defect causing mutagen hypersensitivity in mouse leukemia L1210 cells. Molec Cell Biol 1995; 15: 290-7
27. Koberle B, Masters JRW, Hartley JA, et al. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 1999; 9: 273-6
28. Noble S, Goa KL. Gemcitabine: a review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 1997; 54 (3): 447-72
29. Huang JC, Zamble DB, Reardon JT, et al. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Science USA 1994; 91: 10394-8
30. Vaisman A, Varchenko M, Umar A, et al. The role of hMLH1, hMSH3 and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 1998; 58: 3579-85
31. Chaney SG, Vaisman A. DNA adduct tolerance and bypass. In: Kelland LR, Farrell NP, editors. Platinum-based drugs in cancer therapy. Totowa: Humana Press, 2000: 129-48
32. Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996; 56: 4881-6
33. Brown R. Cisplatin resistance in ovarian cancer: mismatch repair and engagement of apoptosis. In: Kelland LR, Farrell NP, editors. Platinum-based drugs in cancer therapy. Totowa: Humana Press, 2000: 115-28
34. Modrich P. Strand-specific mismatch repair in mammalian cells. J Biol Chem 1997; 272: 24727-30
35. Duckett DR, Drummond JT, Murchie AIH, et al. Human MutSalpha recognises damaged DNA base pairs containing 06-methylguanine, 04-methylthymine or the cisplatin-d(GpG) adduct. Proc Natl Acad Science USA. 1996; 93: 6443-6
36. Fink D, Howell SB. How does cisplatin kill cells? In: Kelland LR, Farrell NP, editors. Platinum-based drugs in cancer therapy. Totowa: Humana Press, 2000: 149-67
37. Lowe SW, Ruley HE, Jacks T, et al. P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-67
38. Eastman A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 1990; 2: 275-80
39. O'Connor PM, Jackman J, Bae I, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth inhibitory potency of 123 anticancer agents. Cancer Res 1997; 57: 4285-300
40. Reed JC. BCL-2 family proteins: role in dysregulation of apoptosis and chemoresistance in cancer. In: Martin SJ, editor. Apoptosis and cancer. Basel: Karger-Landes Systems, 1997: 64-97
41. Beale PJ, Rogers P, Boxall F, et al. BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma. Br J Cancer 2000: 82: 436-40
42. Giaccone G. Clinical perspectives on platinum resistance. Drugs 2000; 59 Suppl. 4: 9-17
43. Rixe O, Ortuzar W, Alvarez M, et al Oxaliplatin, tetraplatin, cisplatin and carboplatin: spectrum of activity in drug-resistant cell lines and in cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 1996; 52: 1855-65
44. Holford J, Sharp SY, Murrer BA, et al. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br J Cancer 1998; 77: 366-73
45. Raynaud FI, Boxall FE, Goddard PM, et al. Cis-amminedichloro(2-methylpyridine) platinum (II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice. Clin Cancer Res 1997; 3: 2063-74
46. Perego P, Caserini C, Gatti L, et al. A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system. Mol Pharmacol 1999; 55: 528-34